Clinical Trial Update: A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating PM8002 in combination with PM1009 as first-line therapy for hepatocellular carcinoma. The trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PM1009
• PM8002

Snippet

Sponsor: Biotheus Inc. | Conditions: HCC, Liver Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING